MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in gastric cancer cells
Authors:
Open Access
- 26 September 2019
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 8 (16) , 7044-7054
Abstract
Background: Immunotherapy and its mechanisms are being studied in a wide variety of cancers. Programmed cell death ligand 1 (PDL1) is associated with immune evasion in numerous tumor types. Here, we aimed to assess the relationship between metastasis associated in colon cancer‐1 (MACC1) and PDL1 and examine their effects on gastric cancer (GC) tumor immunity.Methods: The expression of MACC1, c‐Met, and PDL1 in human GC tissues was first assessed using quantitative RT‐PCR (qRT‐PCR) and immunohistochemistry. We then focused on the relationships among MACC1, c‐Met, and PDL1 using RT‐PCR and western blotting after cell transfection and inhibitor treatment in vitro and on the identification of their roles in immune killing in vitro and in vivo.Results: We found that expression of MACC1, c‐Met, and PDL1 was upregulated in human GC tissues, and there was a positive correlation between the expression levels. In addition, we found that ectopic expression of MACC1 (silencing and overexpression by transfection) resulted in corresponding changes in c‐Met and PDL1 expression levels, and c‐Met/AKT/mTOR pathway inhibitors (SU11274, MK2206, and rapamycin) blocked the regulation of PDL1 expression by MACC1. Furthermore, silencing of MACC1 led to an increase in antitumor and immune killing in vitro and in vivo, and overexpression of MACC1 resulted in a decrease in tumor immunity in vitro and in vivo.Conclusions: From these data, we infer that MACC1 regulates PDL1 expression and tumor immunity through the c‐Met/AKT/mTOR pathway in GC cells and suggest that MACC1 may be a therapeutic target for GC immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (81602489)
This publication has 26 references indexed in Scilit:
- Expression of MACC1 and c-Met in human gastric cancer and its clinical significanceCancer Cell International, 2013
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunityCurrent Opinion in Immunology, 2012
- Osthole Suppresses Hepatocyte Growth Factor (HGF)-Induced Epithelial-Mesenchymal Transition via Repression of the c-Met/Akt/mTOR Pathway in Human Breast Cancer CellsJournal of Agricultural and Food Chemistry, 2011
- The role of signaling pathways in the development and treatment of hepatocellular carcinomaOncogene, 2010
- Inhibition of fatty acid synthase by luteolin post-transcriptionally down-regulates c-Met expression independent of proteosomal/lysosomal degradationMolecular Cancer Therapeutics, 2009
- Inhibitory B7-family molecules in the tumour microenvironmentNature Reviews Immunology, 2008
- HGF/SF-Met signaling in tumor progressionCell Research, 2005
- PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cellsInternational Immunology, 2004
- Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 2003
- Inflammation and cancerNature, 2002